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AbstrAct:
brAFV600E is a constitutively active onco-kinase and is the most common genetic 
alteration in papillary thyroid carcinoma (Ptc), and in anaplastic thyroid 
carcinoma as well, albeit at a lower frequency. the brAFV600E mutation in some 
studies has been significantly associated with extra-thyroidal extension, metastases, 
recurrence, and mortality in patients with PTC. A recent genome-wide expression 
profiling approach (Gene Set Enrichment Analysis (GSEA)) and in vitro and in vivo 
functional studies revealed that brAFV600E affects extracellular matrix composition 
(i.e. increased expression of some collagens and laminins) and promotes thyroid 
cancer migration and invasion. brAFV600E through the phospho-MEK1/2 and 
phospho-ErK1/2 pathway may control a network of genes crucial in integrating 
and regulating the extracellular and intracellular signaling in thyroid cancer cells, 
which may be fundamental to trigger an abnormal cell differentiation/totipotency 
and shape/polarity, and contribute to tumor aggressiveness mechanisms (i.e. 
cell adhesion, migration, and invasion). Increasing our knowledge of brAFV600E-
modulated EcM genes and targeting the subset of genes essential for tumor 
aggressiveness will help establish a novel paradigm for treatment of thyroid 
cancers harboring brAFV600E. Furthermore, identifying downstream events 
from the brAFV600E/ErK1/2 pathway will eventually identify novel biomarkers 
that can be used to correlate with disease outcome and overall survival.  
Thyroid carcinomas of follicular cell origin 
represent the most frequent endocrine malignancy and 
include papillary (PTC), follicular (FTC), and anaplastic 
(ATC) types. PTC with its incidence increasing by almost 
5% each year, currently ranks as the eighth most common 
malignancy diagnosed in women [1]. Surgical treatment, 
thyroid suppressive therapy and radioiodine treatment in 
patients at high risk for recurrence is standard [2]. Some 
clinical factors have been used to predict which patients 
with thyroid cancer might have worse prognoses. Factors 
such as older age (>45 years old), male gender, certain 
histologic subtypes (i.e. tall cell, columnar cell and diffuse 
sclerosing variants of PTC), tumor size greater than 4 cm 
and presence of extrathyroidal extension are associated 
with neck recurrences and distant metastases [3]. 
Activation of the RET/RAS/BRAF/MAPK 
(mitogen-activated extra-cellular signal regulated kinase) 
signaling pathway is the most common oncogenic event 
in PTC tumorigenesis. More recently certain genetic 
alterations in PTCs have been analyzed and some of 
these have also been linked to poorer outcomes.  Most 
PTCs have either a RET/PTC translocation (10–50% of 
PTCs) [4,5], Ras mutations (about 12% of PTCs) [6], or 
the BRAFV600E mutation (29–83% of PTCs) [7-9]. The 
V600E hotspot mutation affects the exon 15 of BRAF, a 
member of the RAF family of kinases, has been recently 
identified  in  PTC.  BRAFV600E can not only initiate Oncotarget 2010; 1:  751 - 756 752 www.impactjournals.com/oncotarget
tumorigenesis in normal thyroid follicular cells but is 
also required to maintain and promote the progression of 
PTC to aggressive PTC [10,11]. Of relevance, BRAFV600E 
oncoprotein elicits elevated kinase activity that leads 
to activation of the MAPK (i.e. MEK1/2 and ERK1/2) 
signaling pathway [12-14]. Some clinical correlative 
studies have pointed to the increased incidence of worse 
histopathologic parameters such as lymphovascular 
invasion, extrathyroidal extension, neck lymph nodal 
disease, and mortality in those with BRAFV600E mutation 
[10,15, 16]. Animal studies also point to an important 
role for this mutation in the aggressive behavior of 
PTCs; thyroid tumors from BRAFV600E transgenic mice 
display extrathyroidal extension and foci of poorly/
undifferentiated thyroid carcinoma [17]. In addition, we 
have recently shown that an orthotopic mouse model of 
ATC cells harboring BRAFV600E mutation and engineered 
to express GFP (Green Fluorescent Protein) displays tumor 
aggressiveness and lymph node and lung metastases that 
recapitulates an advanced human thyroid cancer [18]. 
BRAFV600E is crucially required to maintain and 
promote thyroid cancer progression [19]. Little information 
is known in PTC and ATC about which molecular targets 
of the BRAFV600E mutation and its consequent downstream 
phospho-MEK1/2 and phospho-ERK1/2 kinases 
deregulation leads to this worse prognosis. While it is not 
clearly understood how BRAFV600E mutation leads to more 
aggressive PTCs, altered genes and pathways that have 
been studies include: aberrant methylation of important 
tumor suppressor genes (i.e. TIMP-3), up-regulation of 
metallo-proteases-2, -3, -9 and -13 (MMP-2, -3, -9 and 
-13) expression [20,16], up-regulation of micro-RNAs (i.e. 
miR-146b) [10,21], lower expression of thyroperoxidase 
(TPO) and sodium iodide symporter (NIS) genes (genes 
important for iodine metabolism and iodine cell uptake) 
[22], and chromosomal instability described in rat thyroid 
cells [23].
We have recently investigated how BRAFV600E 
positive PTCs differ in the expression of gene sets and 
found up-regulation of Extracellular Matrix (ECM) 
microenvironment genes in BRAF mutated PTC compared 
with wild type (wt) BRAF PTC or normal thyroid tissue 
[19]. ECM is a three-dimensional structure surrounding 
human cells [24]. ECM is formed of cellular and non-
cellular components. The cellular component includes: 
endothelial  and  lymphatic  cells,  fibroblasts,  immune 
cells (i.e. macrophages, lymphocytes), adipocytes. The 
non-cellular components include soluble factors such as 
growth factors and cytokines, and soluble (e.g. Vascular 
Endothelial Growth Factor (VEGF)) and insoluble 
proteins (e.g. Thrombospondin-1 (TSP-1), Fibronectin 
(FN), collagens, laminins, etc.). The normal ECM had been 
considered for many years as architectural scaffolding but 
many studies over the last decade have shown important 
links between genetic changes in tumor cells and post-
translational modifications (glycosylation, collagens and 
laminins cross-linking, mechanical events such as visco-
elasticity or stiffness, which have been implicated in 
tumorigenesis and tumor invasion) of the ECM proteins. 
These  modifications  then  significantly  alter  tumor  and 
stromal cellular behavior and influence gene expression. 
ECM remodeling in the tumor microenvironment 
represents a complex process able to promote tumor 
growth, adhesion, motility, invasion, enhance cancer cell 
survival, enables metastatic dissemination, and facilitate 
establishment of tumor cells at distant sites [24]. In 
addition, tumor intracellular signal transduction pathways 
cross-talk with the ECM cellular and non-cellular 
components, as well as endothelial cells themselves and 
may lead to angiogenesis, which is another crucial process 
important for tumor progression [25].
DNA microarray-based gene expression signatures 
underlying oncogenic pathways have been used to define 
cancer subtypes, recurrence of disease, and response 
to specific therapies. We have recently used a genome 
wide  expression  profiling  analysis,  GSEA  (Gene  Set 
Enrichment Analysis), to compare the genomic signature 
of PTCs with and without BRAFV600E as well as normal 
thyroid tissue [19].  Our data indicated that out of 539 
gene sets analyzed, 17 up-regulated and one down-
regulated gene sets exclusively linked to the genomic 
signature of BRAFV600E positive PTCs [19]. The up-
regulated gene sets were mainly enriched in leading edge 
genes known to be important in ECM remodeling process 
(i.e. cell adhesion, migration, invasion, and metastasis). 
These 17 up-regulated gene sets included genes involved 
in the following biological processes: “oncogenic KRAS 
signaling”, “cell cycle regulation”, “cell adhesion, 
migration, and invasion”, “cell signaling”, “inflammatory 
and immune mechanisms”, “EGF receptor activation”, 
“cytokines mechanisms”, “estrogen-receptor-dependent 
signal  transduction”,  “vesicular  intracellular  trafficking 
machinery”, “ubiquitination mechanisms”, “caspases 
cascade”, and “platelet aggregation” [19]. The only down-
regulated gene set included genes involved in the tyrosine 
metabolism and in the establishment of differentiation and 
polarity in epithelial cells [19]. 
We  therefore  identified  new  gene  targets  of 
BRAFV600E in PTCs, including those involved in the 
regulation of tumor ECM genes expression (Figure 1). 
Overall, our results demonstrate that the genes listed 
below are positively regulated by BRAFV600E and elicit 
important cellular signaling cross-talks, regulate ECM 
remodeling, and may help explain how this single gene 
mutation triggers thyroid tumor cell migration and 
invasion thus causing a worse clinical picture for patients 
harboring the mutaton [19].  
Some examples of genes important in ECM 
regulation that were discovered to be linked to BRAFV600E 
mutant PTCs [19] included:
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Effects of activated phospho-ErK1/2 signaling pathway by brAFV600E in human thyroid cancer cells. (A) The BRAFV600E 
oncoprotein is constitutively active kinase and does not require Ras signaling to phosphorylate MEK1/2 and ERK1/2 kinases. BRAFV600E elicits 
a strong kinase activity (increased phosphorylation, PO4−) compared with wild type (wt) BRAF and activates MEK1/2 to phospho-MEK1/2 
and ERK1/2 to phospho-ERK1/2, which may be involved in the up-regulation of some ECM remodeling genes (i.e. TSP-1, Fibronectin, 
cathepsins) and ECM receptors (i.e. CD44 and integrin α3, α6, and β1). ECM genes may trigger tumor cell migration and invasion, and cause 
thyroid cancer progression. (B) BRAFV600E knockdown down-regulates phospho-MEK1/2 and phospho-ERK1/2 protein levels and might result 
in inhibition of thyroid cancer progression. (C) Thyroid cancer cells harboring BRAFV600E show an increased ECM stiffness (e.g. collagen or 
laminin cross linking) and disrupts thyroid cell morphogenesis and polarity compared to normal thyroid tissue. This mechanism contributes 
to thyroid cancer progression by increasing cell adhesion, migration, invasion, and metastasis. (D) BRAFV600E knockdown results in decreased 
ECM stiffness and inhibition of thyroid cancer cell migration and invasion.
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TSP-1 is a crucial component of the ECM and 
important regulator of angiogenesis. It is a multifunctional 
matricellular protein (structured with N- and C-terminal 
domains, and 3 types of sequence repeats) that regulates 
ECM structure during tissue genesis. TSP-1 binds to a wide 
variety of integrins (i.e. α3, α6, and β1 involved in cellular 
proliferation and metastasis pathways) and non-integrin 
(i.e. proteoglycans) cell surface receptors, indicating its 
importance in cross-talk between ECM receptors. TSP-1 
together with its target TGFβ1 (that was also significantly 
up-regulated in BRAF mutated PTC) appear to be crucial 
regulator of epithelial cell growth, motility, polarity and 
morphogenesis [26]. 
Integrins (α3, α6, and β1) are the major receptors for 
cell adhesion to the ECM, are also known to interact with 
TSP-1 [27] and initiate ‘outside-in’ signal transduction 
events that modulate gene expression, cell proliferation, 
migration, and invasion [28]. 
cD44
CD44 is a transmembrane receptor for hyaluronic 
acid (HA), which is implicated in various adhesion-
dependent cellular processes, including tumor cell 
migration, invasion, and metastasis [29]. TSP-1 interacts 
with CD44 ligands or HA binding proteins to influence 
CD44 expression [30]. Interestingly, CD44 expression 
is  deficient  in  TSP-1  null  mice  [30].  CD44  cleavage 
is  mediated  by  TGFβ1  through  the  up-regulation  of 
membrane type 1-matrix metalloproteinase and promotes 
migration of melanoma cells [31]. 
FN
FN is another crucial ECM component, which 
interacts with integrins (e.g. α5β1) to regulate cytoskeleton 
organization, cell shape, and proliferation in human cells 
[32]. Fibronectin and TSP-1 can form ternary complex 
and regulate ECM assembly and cell adhesion [33]. There 
is some evidence that changes in integrin expression can 
result in the regulation of secretion of cathepsin-B. The 
12-lipoxygenase metabolite of arachidonic acid that can 
up-regulates surface expression of integrins, induces 
secretion of cathepsin-B from tumor cells [34]. 
cathepsin-b (cts-b) and cathepsin–s
Cathepsin-B (CTS-B) and Cathepsin–S (CTS-S) 
are cysteine proteases and have been implicated in ECM 
remodeling, in particular in processes important for tumor 
development and progression, including angiogenesis, 
cell proliferation and invasion [35]. 
The main level of organization of ECM is the 
basement membrane that interacts directly with the 
epithelium and endothelium and consists primarily of 
collagen IV, laminins, entactin/nidogen and heparin 
sulphate proteoglycans. The second level of organization 
is the interstitial matrix, which is characterized of collagen 
type I and III that along with fibronectin contribute to 
the mechanical strength of the tissue [24]. Importantly, 
we  found  that  collagen  type  I  α1  (COL1A1)  (5-fold 
change), collagen type III α1 (COL3A1) (2-fold change), 
and  laminin  γ2  (LAMC2)  (2.45-fold  change)  were 
significantly increased in BRAFV600E positive PTCs [19].  
These differentially expressed genes may be related to 
the carcinogenesis and progression of malignant thyroid 
growth. These results highlight and reinforce the critical 
role that BRAFV600E plays to up-regulate the expression 
of different ECM non-cellular components by altering 
stoichiometry of interactions between BRAF  mutated 
tumor thyroid cells and ECM molecules, and ultimately 
promoting thyroid cancer cell migration and invasion 
(Figure 1).
As future research continues to focus on finding more 
selective and targeted compounds to truly personalize 
cancer care, researchers will have to be able to understand 
the  molecular  fingerprints  and  subsequent  actions  of 
each one of the mutations in common cancers. Thyroid 
cancer is clearly one of the most studied human cancers 
and many different genetic alterations have been studied. 
Studying how BRAFV600E altered kinase activity in patients 
with PTC creates alterations in the already complex 
tumor cell–ECM interactions has been a logical next 
step for our laboratory. We hope that our work will lead 
to the development of more selective targeted anticancer 
therapies and also biomarkers that may include putative 
effectors (i.e. TSP-1) that may be measurable as secreted-
factors in biologic fluids. To assay candidate biomarkers 
that were emerged from our study will be relevant during 
clinical trials (e.g. using selective inhibitors of BRAFV600E) 
in patients with BRAFV600E positive PTC before treatment 
as  well  as  during  treatment  as  significant  prognostic 
indicators of disease-free and overall survival.
ACknowlEdGEmEnTS
Dr. Carmelo Nucera (M.D., Ph.D.) was a recipient 
of a doctorate Fellowship in Experimental Endocrinology 
and Metabolic Diseases (MIUR, Italy). Drs. Sareh Parangi 
(M.D.), Jack Lawler (PhD), and Richard A. Hodin (M.D.) 
were funded through the NIH Grants.
rEFErENcEs
1.  NCCN. Practice guidelines in Oncology. www.nccn.org. 
2007.
2.  Baudin E, Schlumberger M. New therapeutic approaches 
for metastatic thyroid carcinoma. Lancet Oncol. 2007; 8: 
148-56.Oncotarget 2010; 1:  751 - 756 755 www.impactjournals.com/oncotarget
3.  Schlumberger M, Pacini F. (2003). Prognostic Factors 
(In:Thyroid Tumors Paris Edition Nucleon), pp. 111-25.
4.  Ciampi R, Nikiforov YE. RET/PTC rearrangements and 
BRAF mutations in thyroid tumorigenesis. Endocrinology. 
2007;148: 936-41.
5.  Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio 
G. Molecular mechanisms of RET activation in human 
cancer. Annals of the New York Academy of Sciences. 
2002; 963: 116-21.
6.  Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, 
Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger 
P, Doherty G, Thompson NW, Hanash S, Koenig RJ, 
Nikiforov YE. Molecular classification of papillary thyroid 
carcinoma: distinct BRAF, RAS, and RET/PTC mutation-
specific  gene  expression  profiles  discovered  by  DNA 
microarray analysis. Oncogene. 2005; 24: 6646-56.
7.  Xing M. BRAF mutation in thyroid cancer. Endocrine-
related cancer. 2005; 12: 245-62.
8.  Riesco-Eizaguirre G, Santisteban P. New insights in thyroid 
follicular cell biology and its impact in thyroid cancer 
therapy. Endocrine-related cancer. 2007; 14: 957-77.
9.  Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, 
Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, 
Tuttle  RM,  Ghossein  RA,  Fagin  JA.  Mutational  profile 
of advanced primary and metastatic radioactive iodine-
refractory thyroid cancers reveals distinct pathogenetic 
roles for BRAF, PIK3CA, and AKT1. Cancer research. 
2009; 69: 4885-93.
10. Xing M. BRAF mutation in papillary thyroid cancer: 
pathogenic role, molecular bases, and clinical implications. 
Endocr Rev. 2007; 28: 742-62.
11. Nucera C, Goldfarb M, Hodin R, Parangi S. Role of 
B-Raf(V600E) in differentiated thyroid cancer and 
preclinical validation of compounds against B-Raf(V600E). 
Biochimica et biophysica acta. 2009; 1795: 152-61.
12.  Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg 
S, Teague J, Woffendin H, Garnett MJ, Bottomley W, 
Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, et 
al. Mutations of the BRAF gene in human cancer. Nature. 
2002; 417: 949-54.
13.  Emuss V, Garnett M, Mason C, Marais R. Mutations of 
C-RAF are rare in human cancer because C-RAF has a 
low basal kinase activity compared with B-RAF. Cancer 
research. 2005; 65: 9719-26.
14.  Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, 
Good VM, Jones CM, Marshall CJ, Springer CJ, Barford 
D, Marais R. Mechanism of activation of the RAF-ERK 
signaling pathway by oncogenic mutations of B-RAF. Cell. 
2004; 116: 855-67.
15.  Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, 
Romei C, Miccoli P, Pinchera A, Basolo F. BRAF(V600E) 
mutation and outcome of patients with papillary thyroid 
carcinoma: a 15-year median follow-up study. The Journal 
of clinical endocrinology and metabolism. 2008; 93: 3943-
9.
16.  Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, 
Stella M, Loda M, Vella V, Giordano C, Trimarchi F, 
Mazzon E, Belfiore A, Vigneri R. BRAF(V600E) mutation 
and the biology of papillary thyroid cancer. Endocrine-
related cancer. 2008; 15: 191-205.
17.  Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, 
Refetoff S, Nikiforov YE, Fagin JA. Targeted expression 
of BRAFV600E in thyroid cells of transgenic mice results 
in papillary thyroid cancers that undergo dedifferentiation. 
Cancer research. 2005; 65: 4238-45.
18.  Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler 
J, Nose V, Parangi S. A novel orthotopic mouse model of 
human anaplastic thyroid carcinoma. Thyroid. 2009; 19: 
1077-84.
19.  Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, 
Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, 
Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler 
J, et al. B-Raf(V600E) and thrombospondin-1 promote 
thyroid cancer progression. Proceedings of the National 
Academy of Sciences of the United States of America. 
2010; 107: 10649-54.
20.  Mesa C, Jr., Mirza M, Mitsutake N, Sartor M, Medvedovic 
M, Tomlinson C, Knauf JA, Weber GF, Fagin JA. 
Conditional activation of RET/PTC3 and BRAFV600E in 
thyroid cells is associated with gene expression profiles that 
predict a preferential role of BRAF in extracellular matrix 
remodeling. Cancer research. 2006; 66: 6521-9.
21.  Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee 
YF, Yang KD, Cheng JT, Huang CC, Liu RT. miR-146b is 
highly expressed in adult papillary thyroid carcinomas with 
high risk features including extrathyroidal invasion and the 
BRAF(V600E) mutation. Thyroid. 2010; 20: 489-94.
22.  Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, 
Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A, 
Elisei R. BRAFV600E mutation, but not RET/PTC 
rearrangements, is correlated with a lower expression of 
both thyroperoxidase and sodium iodide symporter genes 
in papillary thyroid cancer. Endocrine-related cancer. 2008; 
15: 511-20.
23.  Mitsutake N, Knauf JA, Mitsutake S, Mesa C, Jr., Zhang 
L, Fagin JA. Conditional BRAFV600E expression 
induces DNA synthesis, apoptosis, dedifferentiation, and 
chromosomal instability in thyroid PCCL3 cells. Cancer 
research. 2005; 65: 2465-73.
24.  Erler JT, Weaver VM. Three-dimensional context regulation 
of metastasis. Clinical & experimental metastasis. 2009; 
26: 35-49.
25.  Folkman J, Watson K, Ingber D, Hanahan D. Induction 
of angiogenesis during the transition from hyperplasia to 
neoplasia. Nature. 1989; 339: 58-61.
26.  Adams JC, Lawler J. Cell-type specific adhesive interactions 
of skeletal myoblasts with thrombospondin-1. Mol Biol 
Cell. 1994; 5: 423-37.Oncotarget 2010; 1:  751 - 756 756 www.impactjournals.com/oncotarget
27.  Chen H, Herndon ME, Lawler J. The cell biology of 
thrombospondin-1. Matrix Biol. 2000; 19: 597-614.
28. Hynes RO. Integrins: bidirectional, allosteric signaling 
machines. Cell. 2002; 110: 673-87.
29.  Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. 
Involvement of CD44, a molecule with a thousand faces, 
in cancer dissemination. Seminars in cancer biology. 2008; 
18: 260-7.
30. Kuznetsova SA, Day AJ, Mahoney DJ, Rugg MS, 
Mosher DF, Roberts DD. The N-terminal module of 
thrombospondin-1 interacts with the link domain of TSG-6 
and enhances its covalent association with the heavy chains 
of inter-alpha-trypsin inhibitor. The Journal of biological 
chemistry. 2005; 280: 30899-908.
31.  Kuo YC, Su CH, Liu CY, Chen TH, Chen CP, Wang 
HS. Transforming growth factor-beta induces CD44 
cleavage that promotes migration of MDA-MB-435s cells 
through the up-regulation of membrane type 1-matrix 
metalloproteinase.  International  journal  of  cancer.  2009; 
124: 2568-76.
32.  Hynes RO. The extracellular matrix: not just pretty fibrils. 
Science. 2009; 326: 1216-9.
33.  Rodrigues RG, Guo N, Zhou L, Sipes JM, Williams SB, 
Templeton NS, Gralnick HR, Roberts DD. Conformational 
regulation of the fibronectin binding and alpha 3 beta 1 
integrin-mediated adhesive activities of thrombospondin-1. 
The Journal of biological chemistry. 2001; 276: 27913-22.
34.  Koblinski JE, Ahram M, Sloane BF. Unraveling the role of 
proteases in cancer. Clin Chim Acta. 2000; 291: 113-35.
35.  Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, 
Peters C, Hanahan D, Joyce JA. Distinct roles for cysteine 
cathepsin genes in multistage tumorigenesis. Genes Dev. 
2006; 20: 543-56.